Special Drug Use Investigation of Xarelto [SPAF].
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 25 May 2017
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Embolism and thrombosis; Stroke
- Focus Adverse reactions
- Acronyms XAPASS
- Sponsors Bayer
- 29 Aug 2016 According to a Bayer media release, the company presented data from this study at European Society of Cardiology (ESC) 2016.
- 13 Nov 2015 Planned End Date changed from 1 Jan 2020 to 1 Mar 2019, as reported by ClinicalTrials.gov.
- 13 Nov 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.